WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Edico Genome
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Genelux Corporation | September 29, 2021
Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...
Cell and Gene Therapy, Industry Outlook
Globenewswire | May 10, 2023
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to detect and treat disease, announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate t...
Texas Children's Hospital | May 09, 2022
Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin. Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...
Industrial Impact, Medical
Genprex, Inc. | December 16, 2022
Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...
Research, Medical
Whitepaper
Cell and Gene Therapy, Medical
Cell and Gene Therapy
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE